NAACCR Item #3955: Derived Rai Stage

Item # Length Source of Standard Year Implemented Version Implemented Year Retired Version Retired
3,955 1 NAACCR 2022 22

NAACCR XML: Tumor.derivedRaiStage


This data item stores the Derived Rai stage value derived from the values coded in the following SSDIs for the Lymphoma-CLL/SLL schema (9823/3).

  • Lymphocytosis [3885]
  • Adenopathy [3804]
  • Organomegaly [3907]
  • Anemia [3811]
  • Thrombocytopenia [3933]

The Rai stage is only applicable for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (9823/3) cases where the primary site is bone marrow (C421). For cases with a primary site other than bone marrow (C421), the derived Rai stage will be 8 and all the SSDIs will be coded to 5.

Derivation will be run on all cases diagnosed 1/1/2018 and forward.


The Derived Rai stage can be used to evaluate disease spread at diagnosis, treatment patterns and outcomes over time.


1Lymphocytosis and Adenopathy
2Lymphocytosis and Organomegaly
(Adenopathy is any value other than 5)
3Lymphocytosis and Anemia
(Adenopathy and Organomegaly are any value other than 5)
4Lymphocytosis and Thrombocytopenia
(Adenopathy, Organomegaly and Anemia are any value other than 5)
8Does not apply, primary site not bone marrow (C421)
(All 5 SSDIs should be set to 5)
(All 5 SSDIs are 9 or blank; at least one is set to 9 OR
Lymphocytosis is 0,7,9 OR
Lymphocytosis is blank and one of the other SSDIs is a value other than 5 or 9)

This field should be left blank for all cases diagnosed prior to 2018, for schemas other than 00795, and when not required by standard setter.